Core Insights - Guangdong is intensifying its focus on the biopharmaceutical industry, leveraging policy benefits and innovation, but still faces deep-seated bottlenecks in R&D, commercialization, market access, and internationalization [1] Group 1: Innovation Mechanisms - The biopharmaceutical R&D process is characterized by high investment, long cycles, and significant risks, necessitating a more inclusive and precise innovation mechanism [1] - A typical original drug takes an average of 12 years from compound selection to market, with R&D costs exceeding $2 billion and a clinical trial failure rate of 90%, highlighting the need for a fault-tolerant mechanism [1] - Establishing a fault-tolerant mechanism could effectively encourage pharmaceutical companies to explore and innovate while maintaining stable growth [1] Group 2: Financial Support and Risk Compensation - A proposal for a provincial biopharmaceutical innovation risk compensation fund aims to provide subsidies for failed R&D projects and support companies purchasing clinical trial insurance [2] - Encouragement for banks to offer credit support to companies with fault-tolerant records and to pilot asset securitization for fault-tolerant projects in Guangzhou and Shenzhen [2] Group 3: Technology and Industry Integration - Emphasis on creating a source of original innovation by leveraging national laboratories and addressing major disease prevention and core technology needs [2] - Increased support for AI-driven innovative drug projects and precise funding for the discovery of original drugs to enhance the global competitiveness of Guangdong's pharmaceutical companies [2] Group 4: Market Access and Internationalization - The importance of market access and internationalization for high-quality industry development is highlighted, with suggestions to utilize the Guangdong-Hong Kong-Macao Greater Bay Area to enhance internationalization levels of pharmaceutical companies [2] - Recommendations to establish a GLP platform recognized internationally to support local pharmaceutical companies in Hong Kong and Macao [2] Group 5: Regulatory and Legal Framework - Proposal to include the Hengqin Guangdong-Macao Deep Cooperation Zone in the "Healthy China" pilot area, allowing for the use of drugs and medical devices already approved in Hong Kong and Macao [3] - Suggestions for establishing a collaborative mechanism for international trademark disputes, integrating resources from various departments to support companies in legal matters [3]